Rhythm Pharmaceuticals, Inc. RYTM Product revenue, net — Total revenues

Other product segments

Similar metrics at other companies

IBRXProduct revenue, net — Total Revenue

$44.17M+168%

BMRNNet product revenues — Total revenues

$760.08M+3.5%

BIIBProduct revenue, net — Total Revenue

$1.75B+1.5%

BBIONet product revenue — Revenue

$180.6M+392%

EXELNet product revenues — Total revenues

$554.98M+8.1%

VRTXProduct revenues, net — Product revenues, net

$2.99B+8.2%

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s product revenue, net — total revenues?

Rhythm Pharmaceuticals, Inc. (RYTM) reported product revenue, net — total revenues of $60.11M in Q1 2026.

How has Rhythm Pharmaceuticals, Inc.'s product revenue, net — total revenues changed year-over-year?

Rhythm Pharmaceuticals, Inc.'s product revenue, net — total revenues increased by 59.4% year-over-year, from $37.72M to $60.11M.

What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s product revenue, net — total revenues?

Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s product revenue, net — total revenues has grown at a 126.0% compound annual growth rate (CAGR), from $16.88M to $194.77M.

What does product revenue, net — total revenues mean?

This metric represents the total net sales generated from the commercialization of the company's proprietary therapeutic products after accounting for returns, rebates, and discounts. It serves as a primary indicator of market adoption and the successful transition from clinical development to commercial-stage revenue generation for rare disease treatments. Monitoring this figure helps investors assess the scalability and commercial trajectory of the company's core pharmaceutical portfolio.